文献速递中医内科中药与中成药合理使用

脱敏定喘汤通过抑制肥大细胞脱颗粒及下调差异表达蛋白缓解卵清蛋白诱导的过敏性哮喘

Tuo-Min-Ding-Chuan Decoction Alleviate Ovalbumin-Induced Allergic Asthma by Inhibiting Mast Cell Degranulation and Down-Regulating the Differential Expression Proteins.
PubMed 文献 · Front Pharmacol · 2021-09-22

本研究探讨脱敏定喘汤(TMDCD)对卵清蛋白(OVA)诱导的过敏性哮喘小鼠的作用及免疫调节机制。结果显示TMDCD可减轻气道高反应性、炎症细胞浸润和黏液分泌,降低血清总IgE、OVA特异性IgE、组胺和LTC4水平,下调多种差异表达蛋白,并在体外抑制RBL-2H3细胞脱颗粒。

要点

  • TMDCD可减轻OVA诱导哮喘小鼠的气道炎症和气道重塑。
  • TMDCD降低血清IgE、组胺、LTC4及多种肥大细胞相关蛋白水平。
  • TMDCD体外抑制IgE介导的RBL-2H3细胞脱颗粒和组胺释放。

核心结论

  • TMDCD可减轻过敏性哮喘小鼠肺部炎症细胞浸润和气道重塑,具有抗炎平喘作用。
  • TMDCD可降低血清IgE、组胺、LTC4及肥大细胞相关蛋白水平,并抑制肥大细胞脱颗粒。

研究设计与样本

  • 研究采用卵清蛋白(OVA)诱导的过敏性哮喘小鼠模型及体外RBL-2H3细胞实验。

主要发现

  • TMDCD降低OVA激发小鼠的气道高反应性、肺组织炎症细胞浸润和黏液分泌。
  • TMDCD降低血清总IgE、OVA特异性IgE、组胺和LTC4水平。
  • TMDCD下调血清中Fractalkine、Tryptase ε、IL-25、CCL19、MCP-1、OX40L、Axl、CCL22、CD30、G-CSF、E-selectin、OPN、CCL5、P-selectin、Gas6、TSLP等蛋白表达。
  • 体外实验显示TMDCD抑制DNP-IgE/BSA刺激的RBL-2H3细胞脱颗粒。

临床怎么用

  • TMDCD可能通过抑制肥大细胞脱颗粒和下调相关炎症蛋白,用于过敏性哮喘的辅助治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allergic asthma is a stubborn chronic inflammatory disease, and is considered a co-result of various immune cells, especially mast cells, eosinophils and T lymphocytes. At present, the treatment methods of allergic asthma are limited and the side effects are obvious. Traditional Chinese medicine has been used to treat diseases for thousands of years in China. One such example is the treatment of allergic asthma, which take the characteristics of less adverse reactions and obvious curative effect. Tuo-Min-Ding-Chuan Decoction (TMDCD) is a traditional Chinese medicine compound for the treatment of allergic asthma optimized from Ma-Xing-Gan-Shi Decoction (MXGSD), which was put forward in Treatise on Febrile Diseases by Zhang Zhongjing in the Eastern Han Dynasty. The compound shows a significant clinical effect, but the mechanism of its influence on the immune system is still unclear. The purpose of this study was to observe whether TMDCD could alleviate the symptoms of ovalbumin (OVA) challenged allergic asthma mice, and to explore its immune regulatory mechanism, especially on mast cell (MC) degranulation. The results showed TMDCD could not only reduce the airway hyperresponsiveness (AHR), inflammatory cell infiltration and mucus secretion in the lung tissue of OVA challenged mice, but also decrease the levels of total IgE, OVA-specific IgE, histamine and LTC4 in serum. We found that TMDCD can downregulate the expression of Fractalkine, Tryptase ε, IL-25, CCL19, MCP-1, OX40L, Axl, CCL22, CD30, G-CSF, E-selectin, OPN, CCL5, P-selectin, Gas6, TSLP in OVA challenged mice serum by using mouse cytokines antibody array. It has been reported in some literatures that these differentially expressed proteins are related to the occurrence of allergic asthma, such as tryptase ε, MCP-1, CCL5, etc. can be released by MC. And the results of in vitro experiments showed that TMDCD inhibited the degranulation of RBL-2H3 cells stimulated by DNP-IgE/BSA. Taken together, we made the conclusion that TMDCD could reduce the infiltration of inflammatory cells in lung tissue and alleviate airway remodeling in mice with allergic asthma, showed the effects of anti-inflammatory and antiasthmatic. TMDCD could also reduce the levels of IgE, histamine, LTC4, Tryptase ε, and other MC related proteins in the serum of allergic asthma mice, and the in vitro experiments showed that TMDCD could inhibit IgE mediated degranulation and histamine release of RBL-2H3 cells, proved its anti allergic effect.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Qin J, Lv M, Jiang Z, et al. Tuo-Min-Ding-Chuan Decoction Alleviate Ovalbumin-Induced Allergic Asthma by Inhibiting Mast Cell Degranulation and Down-Regulating the Differential Expression Proteins. Front Pharmacol. 2021. PMID: 34630102. doi:10.3389/fphar.2021.725953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。